John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Three unlikely winners of 2024 can lead the way in the year ahead. Some of the hottest stocks of 2024 may surprise you. A few ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Alongside telehealth, Hims & Hers has a range of non-prescription wellness products such as melatonin and biotin, skincare products such as moisturizers and sunscreen, and sex products such as ...

Hot telehealth stock Hims & Hers Health (NYSE: HIMS) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high. Yet Hims & Hers is still up nearly ...

Hims & Hers sells compounded GLP-1 agonists, which have become its identity in the eyes of the market. The company is poised to grow, even if it must shut down its compounded GLP-1 agonist ...